| Liraglutide and cardiovascular outcomes in type 2 diabetes SP Marso, GH Daniels, K Brown-Frandsen, P Kristensen, JFE Mann, ... New England Journal of Medicine 375 (4), 311-322, 2016 | 2903 | 2016 |
| Alogliptin after acute coronary syndrome in patients with type 2 diabetes WB White, CP Cannon, SR Heller, SE Nissen, RM Bergenstal, GL Bakris, ... New England Journal of Medicine 369 (14), 1327-1335, 2013 | 2105 | 2013 |
| Evolocumab and clinical outcomes in patients with cardiovascular disease MS Sabatine, RP Giugliano, AC Keech, N Honarpour, SD Wiviott, ... New England Journal of Medicine 376 (18), 1713-1722, 2017 | 2036 | 2017 |
| Lixisenatide in patients with type 2 diabetes and acute coronary syndrome MA Pfeffer, B Claggett, R Diaz, K Dickstein, HC Gerstein, LV Køber, ... New England Journal of Medicine 373 (23), 2247-2257, 2015 | 1216 | 2015 |
| Follow-up of blood-pressure lowering and glucose control in type 2 diabetes S Zoungas, J Chalmers, B Neal, L Billot, Q Li, Y Hirakawa, H Arima, ... New England Journal of Medicine 371 (15), 1392-1406, 2014 | 483 | 2014 |
| Psychological well‐being in patients on ‘adequate’ doses of l‐thyroxine: results of a large, controlled community‐based questionnaire study P Saravanan, WF Chau, N Roberts, K Vedhara, R Greenwood, CM Dayan Clinical endocrinology 57 (5), 577-585, 2002 | 452 | 2002 |
| Liraglutide and renal outcomes in type 2 diabetes JFE Mann, DD Ørsted, K Brown-Frandsen, SP Marso, NR Poulter, ... New England Journal of Medicine 377 (9), 839-848, 2017 | 367 | 2017 |
| Efficacy and safety of degludec versus glargine in type 2 diabetes SP Marso, DK McGuire, B Zinman, NR Poulter, SS Emerson, TR Pieber, ... New England Journal of Medicine 377 (8), 723-732, 2017 | 321 | 2017 |
| Common Variation in the DIO2 Gene Predicts Baseline Psychological Well-Being and Response to Combination Thyroxine Plus Triiodothyronine Therapy in … V Panicker, P Saravanan, B Vaidya, J Evans, AT Hattersley, TM Frayling, ... The Journal of Clinical Endocrinology & Metabolism 94 (5), 1623-1629, 2009 | 276 | 2009 |
| Thyroid autoantibodies P Saravanan, CM Dayan Endocrinology and Metabolism Clinics of North America 30 (2), 315-337, 2001 | 186 | 2001 |
| Cognitive function in a randomized trial of evolocumab RP Giugliano, F Mach, K Zavitz, C Kurtz, K Im, E Kanevsky, J Schneider, ... New England Journal of Medicine 377 (7), 633-643, 2017 | 182 | 2017 |
| Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets JH DeVries, SC Bain, HW Rodbard, J Seufert, D D’Alessio, AB Thomsen, ... Diabetes care 35 (7), 1446-1454, 2012 | 178 | 2012 |
| High fat intake leads to acute postprandial exposure to circulating endotoxin in type 2 diabetic subjects AL Harte, MC Varma, G Tripathi, KC McGee, NM Al-Daghri, OS Al-Attas, ... Diabetes care 35 (2), 375-382, 2012 | 139 | 2012 |
| Partial Substitution of Thyroxine (T4) with Tri-Iodothyronine in Patients on T4 Replacement Therapy: Results of a Large Community-Based Randomized Controlled … P Saravanan, DJ Simmons, R Greenwood, TJ Peters, CM Dayan The Journal of Clinical Endocrinology & Metabolism 90 (2), 805-812, 2005 | 128 | 2005 |
| A Common Variation in Deiodinase 1 Gene DIO1 Is Associated with the Relative Levels of Free Thyroxine and Triiodothyronine V Panicker, C Cluett, B Shields, A Murray, KS Parnell, JRB Perry, ... The Journal of Clinical Endocrinology & Metabolism 93 (8), 3075-3081, 2008 | 120 | 2008 |
| The identification of irisin in human cerebrospinal fluid: influence of adiposity, metabolic markers, and gestational diabetes MK Piya, AL Harte, K Sivakumar, G Tripathi, PD Voyias, S James, ... American Journal of Physiology-Endocrinology and Metabolism 306 (5), E512-E518, 2014 | 93 | 2014 |
| Psychological well-being correlates with free thyroxine but not free 3, 5, 3′-triiodothyronine levels in patients on thyroid hormone replacement P Saravanan, TJ Visser, CM Dayan The Journal of Clinical Endocrinology & Metabolism 91 (9), 3389-3393, 2006 | 85 | 2006 |
| Whose normal thyroid function is better--yours or mine? CM Dayan, P Saravanan, G Bayly The Lancet 360 (9330), 353-354, 2002 | 85 | 2002 |
| Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo R Bentley-Lewis, D Aguilar, MC Riddle, B Claggett, R Diaz, K Dickstein, ... American heart journal 169 (5), 631-638. e7, 2015 | 79 | 2015 |
| GLP-1 analogue, Liraglutide protects human umbilical vein endothelial cells against high glucose induced endoplasmic reticulum stress B Schisano, AL Harte, K Lois, P Saravanan, N Al-Daghri, O Al-Attas, ... Regulatory peptides 174 (1-3), 46-52, 2012 | 74 | 2012 |
